BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 31,500 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00. Following the transaction, the chief executive officer directly owned 781,709 shares of the company's stock, valued at $80,922,515.68. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.
BioNTech Stock Performance
Shares of BNTX stock opened at $98.66 on Wednesday. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The company's fifty day simple moving average is $96.94 and its 200-day simple moving average is $95.55. The firm has a market cap of $24.95 billion, a PE ratio of -12.60 and a beta of 1.29. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period last year, the business posted ($1.60) EPS. The firm's revenue for the quarter was down 59.5% on a year-over-year basis. Equities research analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.
Institutional Trading of BioNTech
Institutional investors and hedge funds have recently bought and sold shares of the business. Monaco Asset Management SAM acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $1,594,000. Hsbc Holdings PLC bought a new stake in BioNTech in the 4th quarter valued at $4,969,000. Bank of America Corp DE lifted its holdings in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after purchasing an additional 166,432 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Finally, Amundi boosted its position in BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company's stock worth $11,511,000 after purchasing an additional 25,506 shares during the period. Institutional investors own 15.52% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on BNTX shares. UBS Group raised BioNTech from a "neutral" rating to a "buy" rating and lifted their target price for the company from $117.00 to $135.00 in a research report on Wednesday, May 27th. Berenberg Bank decreased their price target on BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a research note on Tuesday, May 12th. Wall Street Zen lowered BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. BMO Capital Markets cut BioNTech from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $128.00 to $105.00 in a research note on Tuesday. Finally, Jefferies Financial Group reissued a "buy" rating on shares of BioNTech in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $126.00.
Check Out Our Latest Stock Report on BioNTech
BioNTech Company Profile
(
Get Free Report)
BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
